Revolutionary New Airborne Particle Counter Released by Biotest
Biotest AG has launched its unique APC SmartTouch Airborne Particle Counter specifically designed for flow rates of both one cubic foot per minute (1 CFM) and 100 liters per minute (100 L/min), thereby significantly reducing cleanroom certification and monitoring costs. It supports fast and convenient color touchscreen handling and is equipped with two high-capacity batteries for flexible, continuous sampling. To minimize the likelihood of human sampling errors, a plan of the sample locations can be displayed on the touchscreen.
“With its exciting and unique features, the APC SmartTouch system is truly in a class of its own. For airborne particle counting in the pharma, biotech, medical device and sensitive food industries, there is currently nothing that matches its flexibility and convenience. It’s simply the smartest,” says Dr Frank Schulze, Executive Vice President Microbiology at Biotest AG.
Due to the different flow rates required for cleanroom filter testing (ISO 14644-1) and monitoring (ISO 14644-2), two different particle counters are usually employed. The APC SmartTouch eliminates the need to invest in multiple instruments, thereby also reducing the costs of the associated routine calibration events.
The APC SmartTouch features a large interactive color touchscreen with commonly used icons for easy and intuitive operation. All required actions start from the main screen, thus there is no need to access any submenus. This increases operating efficiency and saves considerable time.
For a visual representation of the sampling locations, including the designated sampling points, a graphic file is imported into the APC SmartTouch. By confirming that the proper samples have been taken, the potential for sampling errors is minimized. The instrument’s utility software stores designated sample location names for greater user convenience and allows defined parameter recipes such as counting mode, count time and initial wait time to be created.
The instrument is available in either stainless steel or plastic with stainless steel components. To eliminate the need for downtime during recharging, each instrument is equipped with slots for two long-lasting lithium ion batteries. In the plastic enclosure variant they are retrievable even during use, enabling uninterrupted operation and thus ensuring maximum flexibility.
The APC SmartTouch is ideally suited for disinfection and fulfills the most stringent hygiene standards. It comes as a complete package system, including many accessories such as a stainless steel isokinetic probe and a zero count filter.
About Biotest Microbiology
Biotest Microbiology, a Global Business Unit of Biotest AG is involved in the research, development, manufacturing and distribution of products for the determination of microbiological and particulate contamination of cleanrooms and other controlled environments, as well as products for detection and identification of microbes for industrial applications.
Biotest Microbiology includes the HYCON® range of products for hygiene control (RCS Microbial Air Sampler, APC Airborne Particle Counter), MMB (Molecular biology) products for detection and quantitation of microbes by real-time molecular methods and test for quality control of end products, such as the PyroDetect system for detecting pyrogens. It also includes heipha Dr. Müller GmbH, an affiliate company specializing in the complete range of plated and liquid agar media for industrial applications.
For more information please visit http://www.biotest.com
Biotest is a provider of pharmaceutical and biotherapeutic drugs as well as reagents and systems for microbiology. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialized primarily in the areas of application of immunology and hematology. In its Plasma Protein segment, Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems.
In the Biotherapeutic segment, Biotest researches into the clinical development of monoclonal antibodies, including in the indications of rheumatoid arthritis and cancer of plasma cells. The products of the Microbiological Monitoring segment are primarily used in hygiene monitoring. Biotest has more than 1,900 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.